ATE324881T1 - Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen - Google Patents

Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen

Info

Publication number: ATE324881T1
Authority: AT; Austria
Prior art keywords: disubstituted; methods; trans; antagonists; therapeutic agents
Prior art date: 2000-08-09

Application number

AT01961984T

Other languages

English (en)

Inventor

Ibert C Wells

Original Assignee

Magnesium Diagnostics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-09

Filing date

2001-08-09

Publication date

2006-06-15

2001-08-09 Application filed by Magnesium Diagnostics Inc filed Critical Magnesium Diagnostics Inc

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE324881T1 publication Critical patent/ATE324881T1/de

Links

238000000034 method Methods 0.000 title abstract 3
229910052749 magnesium Inorganic materials 0.000 title abstract 2
239000011777 magnesium Substances 0.000 title abstract 2
230000002159 abnormal effect Effects 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
230000002950 deficient Effects 0.000 title 1
239000003814 drug Substances 0.000 title 1
230000004962 physiological condition Effects 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
-1 1,2-disubstituted trans ethylenes Chemical class 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical class C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 abstract 1
208000007530 Essential hypertension Diseases 0.000 abstract 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical class CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000000170 cell membrane Anatomy 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT01961984T 2000-08-09 2001-08-09 Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen ATE324881T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/635,266 US6455734B1 (en)	2000-08-09	2000-08-09	Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states

Publications (1)

Publication Number	Publication Date
ATE324881T1 true ATE324881T1 (de)	2006-06-15

Family

ID=24547100

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01961984T ATE324881T1 (de)	2000-08-09	2001-08-09	Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen

Country Status (9)

Country	Link
US (12)	US6455734B1 (de)
EP (1)	EP1355638B1 (de)
JP (1)	JP2004508299A (de)
AT (1)	ATE324881T1 (de)
AU (1)	AU2001283203A1 (de)
CA (1)	CA2418951A1 (de)
DE (1)	DE60119385D1 (de)
NZ (1)	NZ523915A (de)
WO (1)	WO2002011714A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040171093A1 (en) *	1999-03-10	2004-09-02	Wells Ibert C.	Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
US6372440B2 (en) *	1999-03-10	2002-04-16	Magnesium Diagnostics, Inc.	Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
JP2009524617A (ja)	2006-01-27	2009-07-02	エフ．ホフマン−ラロシュアーゲー	置換２−イミダゾール又はイミダゾリン誘導体の使用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL142416B (nl) *	1969-04-30	1974-06-17	Univ Osaka	Werkwijze voor het bereiden van 6-amino-acylaminopenicillanzuren, alsmede werkwijze voor de bereiding van farmaceutische preparaten.
US4097472A (en)	1974-11-08	1978-06-27	Mitsubishi Chemical Industries Limited	N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
US4073913A (en)	1974-11-08	1978-02-14	Mitsubishi Chemical Industries Limited	N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
FR2166316A1 (en) *	1972-01-07	1973-08-17	Toyama Chemical Co Ltd	7-acylcephalosporins - prepd via a silylated inter
IL42124A (en)	1972-05-02	1977-02-28	Kabi Ab	Substrate for the determination of proteolytic enzymes
US3894995A (en)	1972-12-26	1975-07-15	Hoechst Ag	Transparent polyamides from an isomeric mixture of norbornanes
US3885136A (en) *	1974-02-25	1975-05-20	Gulf & Western Industries	Reset timer/counter unit
US4201863A (en)	1974-11-08	1980-05-06	Mitsubishi Chemical Industries, Limited	N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4144244A (en)	1977-12-27	1979-03-13	Ciba-Geigy Corporation	Perfluoroalkyl-iodo norbornane dicarboxylic acids and derivatives thereof
US4304771A (en)	1979-07-13	1981-12-08	Usv Pharmaceutical Corporation	Antihypertensive amides
US4352751A (en)	1979-09-10	1982-10-05	Analytical Radiation Corporation	Species-linked diamine triacetic acids and their chelates
US4331570A (en)	1980-07-17	1982-05-25	International Flavors & Fragrances Inc.	Carboamidoalkyl norbornanes and organoleptic use in perfumes
US4532342A (en)	1981-02-20	1985-07-30	Warner-Lambert Company	N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
AU564576B2 (en) *	1981-09-24	1987-08-20	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Purine derivatives
US4609661A (en) *	1982-08-09	1986-09-02	Syntex (U.S.A.) Inc.	Substituted 9-(1-O- or 3-O-monosubstituted or 1,3-di-O-substituted propoxymethyl)purines as antiviral agents
DE3401949A1 (de)	1984-01-20	1985-08-01	Bayer Ag, 5090 Leverkusen	Norbornan- und norbornencarbonsaeureamide, verfahren zu deren herstellung sowie die verwendung von norbornan- und norbornencarbonsaeureamiden als arzneimittel
US4761481A (en)	1985-03-18	1988-08-02	Baxter Travenol Laboratories, Inc.	Substituted pyridine derivatives
DE8517666U1 (de) *	1985-06-18	1985-08-14	Heinrich Baumgarten KG, Spezialfabrik für Beschlagteile, 5908 Neunkirchen	Geschirrgriff für die Befestigung an Bolzen
US4705897A (en)	1986-05-05	1987-11-10	Texaco Inc.	Process for producing bicyclic diamines
US4772607A (en)	1986-05-20	1988-09-20	Warner-Lambert Company	Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
GB8613431D0 (en)	1986-06-03	1986-07-09	Medical Res Council	Human tachykinins
IL83966A (en)	1986-09-26	1992-03-29	Schering Ag	Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them
GB2200115B (en) *	1987-01-21	1990-11-14	Sandoz Ltd	Novel peptide derivatives, their production and use
US4792555A (en)	1987-03-20	1988-12-20	American Home Products Corporation	Phospholipase A2 inhibitors
US5128346A (en)	1987-09-21	1992-07-07	Abbott Laboratories	Derivatives of D-glutamic acid and D-aspartic acid
DE3804793A1 (de)	1988-02-16	1989-08-24	Hoechst Ag	Renin-hemmende aminosaeurederivate
US5256645A (en)	1988-03-04	1993-10-26	Hoffmann-La Roche Inc.	Amino acid derivatives
CA1328333C (en)	1988-03-04	1994-04-05	Quirico Branca	Amino acid derivatives
JPH02209861A (ja)	1988-05-06	1990-08-21	Ono Pharmaceut Co Ltd	アミノ酸誘導体及び該誘導体を有効成分として含有するエンケファリナーゼ阻害剤
US5177089A (en) *	1988-06-01	1993-01-05	Eisai Co., Ltd.	Butenoic or propenoic acid derivative
CA1340588C (en)	1988-06-13	1999-06-08	Balraj Krishan Handa	Amino acid derivatives
JPH0225417A (ja) *	1988-07-12	1990-01-26	Asahi Chem Ind Co Ltd	抗潰瘍剤
FR2640970A1 (en) *	1988-12-28	1990-06-29	Pf Medicament	"Z"-1-Phenyl-2-(aminomethyl)cyclopropanecarboxamide derivatives and their therapeutic application
US5049548A (en) *	1989-03-03	1991-09-17	Merck & Co., Inc.	Renin-inhibitory di-, tri-, and tetrapeptides
US5616562A (en)	1990-04-27	1997-04-01	Murphy; Christopher J.	Methods and compositions using substance P to promote wound healing
IE920175A1 (en)	1991-02-11	1992-08-12	Zeneca Ltd	Nitrogen heterocycles
FR2676734B1 (fr)	1991-05-23	1995-05-19	Roussel Uclaf	Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
US6011068A (en) *	1991-08-23	2000-01-04	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
EP0532466A3 (en) *	1991-09-12	1993-06-16	Ciba-Geigy Ag	Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
US5527790A (en) *	1991-09-30	1996-06-18	The University Of British Columbia	Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
JP3122520B2 (ja)	1992-03-13	2001-01-09	生化学工業株式会社	２−アミノピリジン誘導体、その製造方法及び蛍光標識剤
JP2578044B2 (ja)	1992-03-14	1997-02-05	呉羽化学工業株式会社	フェニルアラニン−グリシン誘導体、その製造方法、及びその誘導体を含有する抗腫瘍剤
US5506227A (en)	1992-04-13	1996-04-09	Merck Frosst Canada, Inc.	Pyridine-substituted benzyl alcohols as leukotriene antagonists
EP1000930A3 (de)	1992-08-13	2003-10-29	Warner-Lambert Company	Tachykinin Antagoniste
US5641783A (en)	1993-11-12	1997-06-24	Cell Therapeutics, Inc.	Substituted amino alcohol compounds
AU680870B2 (en)	1993-04-28	1997-08-14	Astellas Pharma Inc.	New heterocyclic compounds
JP3548205B2 (ja) *	1993-10-29	2004-07-28	キヤノン株式会社	画像処理方法およびその装置
US6403577B1 (en)	1993-11-17	2002-06-11	Eli Lilly And Company	Hexamethyleneiminyl tachykinin receptor antagonists
CA2109684C (en) *	1993-11-22	2002-03-19	Peter A. Pubben	Faucet control device
US5492927A (en)	1993-12-21	1996-02-20	Eli Lilly And Company	Non-peptide tachykinin receptor antagonists to treat allergy
ITFI940009A1 (it)	1994-01-19	1995-07-19	Menarini Farma Ind	Antagonisti delle tachichinine, loro preparazione e formulazioni farmaceutiche che li contengono.
US5646155A (en)	1994-05-12	1997-07-08	University Of Massachusetts Medical Center	Drugs to prevent recurrent herpes virus infections
ATE206710T1 (de)	1994-06-06	2001-10-15	Warner Lambert Co	Tachykinin (nk1) rezeptor antagonisten
US5491140A (en)	1994-06-30	1996-02-13	Eli Lilly And Company	Naphthyl tachykinin receptor antagonists to treat physiological conditions
TW307746B (de) *	1994-10-14	1997-06-11	Sumitomo Chemical Co
WO1996013485A1 (en)	1994-10-27	1996-05-09	Fujisawa Pharmaceutical Co., Ltd.	Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists
US5607947A (en)	1995-02-21	1997-03-04	Eli Lilly And Company	Pyrrolidinyl tachykinin receptor antagonists
US5563133A (en)	1995-02-21	1996-10-08	Eli Lilly And Company	Hexamethyleneiminyl tachykinin receptor antagonists
US5565568A (en)	1995-04-06	1996-10-15	Eli Lilly And Company	2-acylaminopropanamides as tachykinin receptor antagonists
WO1997011940A1 (en)	1995-09-29	1997-04-03	Eli Lilly And Company	Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
AU7475396A (en) *	1995-10-30	1997-05-22	Merck & Co., Inc.	Novel inhibitors of peptide binding to mhc class ii proteins
CA2191924A1 (en) *	1995-12-05	1997-06-06	Kevin Felsenstein	5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of .beta.-amyloid protein production
WO1997040011A1 (en)	1996-04-23	1997-10-30	R. J. Reynolds Tobacco Company	Pharmaceutical compositions for prevention and treatment of central nervous system disorders
DE19629816A1 (de)	1996-07-24	1998-01-29	Hoechst Ag	Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5703173A (en) *	1996-08-16	1997-12-30	Integument Technologies, Inc.	Transition metallohalopolymers
GB9617305D0 (en)	1996-08-17	1996-09-25	Glaxo Wellcome Spa	Heterocyclic compounds
CA2239227C (en)	1996-10-01	2007-10-30	Kyowa Hakko Kirin Co., Ltd.	Nitrogen-containing heterocyclic compounds
EA199900375A1 (ru)	1996-11-14	1999-12-29	Пфайзер Инк.	Способ получения замещенных пиридинов
JPH10177774A (ja)	1996-12-16	1998-06-30	Fujitsu Ltd	ディスク装置及び携帯型電子装置
PE46999A1 (es) *	1996-12-17	1999-05-20	Warner Lambert Co	Inhibidores de cicloalquilo de la enzima farnesiltransferasa de las proteinas
US6559144B2 (en)	1997-02-13	2003-05-06	Merck Patent Gesellschaft Mit	Bicyclic amino acids
ES2207834T3 (es)	1997-04-22	2004-06-01	Janssen Pharmaceutica N.V.	Quino- y quinazolinas antagonistas del crf.
US6245760B1 (en)	1997-05-28	2001-06-12	Aventis Pharmaceuticals Products, Inc	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en)	1997-05-28	2001-01-30	Aventis Pharmaceuticals Products Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
WO1998057931A2 (en)	1997-06-19	1998-12-23	Sepracor Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6015815A (en)	1997-09-26	2000-01-18	Abbott Laboratories	Tetrazole-containing rapamycin analogs with shortened half-lives
ES2352739T3 (es) *	1997-11-21	2011-02-22	Purdue Neuroscience Company	2-aminoacetamidas sustituidas y el uso de las mismas.
US6174901B1 (en)	1998-12-18	2001-01-16	Amgen Inc.	Substituted pyridine and pyridazine compounds and methods of use
US6011066A (en) *	1998-02-02	2000-01-04	Veterans General Hospital-Taipei	Method for treating septic shock
US6133455A (en) *	1998-02-09	2000-10-17	American Cyanamid Company	Process for the preparation of 2-aryl-5(perfluoro-alkyl) pyrrole compounds from N-(arylmethylene)-1-chloro-1-(perfluoroalkyl) methylamine compounds
US6689754B1 (en)	1998-04-10	2004-02-10	G. D. Searle & Co.	Heterocyclic glycyl β-alanine derivatives
GEP20032996B (en) *	1998-05-12	2003-06-25	Warner Lambert Co	Combinations of Protein Farnesyltransferase and HMG CoA Reductase Inhibitors, Pharmaceutical Compositions and Methods for Treatment
GB9811969D0 (en)	1998-06-03	1998-07-29	Celltech Therapeutics Ltd	Chemical compounds
MY125037A (en)	1998-06-10	2006-07-31	Glaxo Wellcome Spa	1,2,3,4 tetrahydroquinoline derivatives
US6417185B1 (en)	1998-06-19	2002-07-09	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
US6090942A (en)	1998-10-15	2000-07-18	Pfizer Inc.	Process and intermediates for a β3 -adrenergic receptor agonist
TWI243192B (en) *	1998-12-31	2005-11-11	Ciba Sc Holding Ag	Phthalimidyl azo pigments, method for producing same and utilization thereof
WO2000051998A1 (en)	1999-03-02	2000-09-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cathepsin s
AT407993B (de) *	1999-03-03	2001-07-25	Voest Alpine Ind Anlagen	Verfahren zur optimierung von auslegung und betrieb eines reduktionsverfahrens
US6372440B2 (en)	1999-03-10	2002-04-16	Magnesium Diagnostics, Inc.	Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
US6750348B1 (en)	1999-03-24	2004-06-15	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
US6380210B1 (en) *	1999-04-02	2002-04-30	Neurogen Corporation	Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
WO2000059874A1 (en)	1999-04-02	2000-10-12	Du Pont Pharmaceuticals Company	NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
SG82692A1 (en) *	1999-04-07	2001-08-21	Sumitomo Chemical Co	Method for purifying beta-phenylethyl alcohol
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
US20020169101A1 (en) *	1999-05-10	2002-11-14	Gonzalez Maria Isabel	Treatment of sexual dysfunction
JP2001079018A (ja) *	1999-09-14	2001-03-27	Gc Corp	歯科用自動切削加工装置
US6369729B1 (en) *	1999-10-08	2002-04-09	Cirrus Logic, Inc.	Common mode shift in downstream integrators of high order delta sigma modulators
CZ20021911A3 (cs) *	1999-12-03	2002-10-16	Kyoto Pharmaceutical Industries, Ltd.	Nové heterocyklické sloučeniny a jejich soli a jejich vyuľití v lékařství
PT1237880E (pt)	1999-12-17	2008-03-05	Novartis Vaccines & Diagnostic	Inibidores baseados em pirazina da cinase 3 da glicogénio sintase
US6328386B1 (en) *	2000-01-11	2001-12-11	Takata Seat Belts Inc.	Seat belt system
US6656958B2 (en)	2000-02-02	2003-12-02	Abbott Laboratories	Substituted pyridine compounds useful for controlling chemical synaptic transmission
US6593340B1 (en) *	2000-02-28	2003-07-15	Cv Technologies, Inc.	Pharmaceutical compositions containing N-propargylphentermine and related analogs to treat neurodegeneration and/or depression
AU2001250850A1 (en)	2000-03-17	2001-10-03	Dupont Pharmaceuticals Company	Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
CA2408343A1 (en) *	2000-05-11	2002-11-07	Banyu Pharmaceutical Co., Ltd.	N-acyltetrahydroisoquinoline derivatives
US6539771B1 (en) *	2000-05-12	2003-04-01	Delphi Technologies, Inc.	Seat sensor calibration method and system
US20030087915A1 (en)	2000-05-12	2003-05-08	Dull Gary Maurice	Pharmaceutical compositions and methods for use
DE50107913D1 (de) *	2000-05-23	2005-12-08	Dyomics Gmbh	Stabile nir-marker-farbstoffe auf der basis von benzopyrylium-polymethinen
DE10028402A1 (de)	2000-06-13	2001-12-20	Merck Patent Gmbh	Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US20020173507A1 (en)	2000-08-15	2002-11-21	Vincent Santora	Urea compounds and methods of uses
US6583153B2 (en)	2000-12-12	2003-06-24	Ortho-Mcneil Pharmaceutical, Inc.	7-heterocyclyl quinoline and thieno[2,3-b]yridine derivatives useful as antagonists of gonadotropin releasing hormone
US6943250B2 (en) *	2001-03-06	2005-09-13	Fmc Corporation	Protected aminofunctionalized polymerization initiators and methods of making and using same
WO2002079163A1 (en)	2001-03-30	2002-10-10	Smithkline Beecham Corporation	Aminopyridine derivatives as estrogen receptor modulators
US6911447B2 (en)	2001-04-25	2005-06-28	The Procter & Gamble Company	Melanocortin receptor ligands
MXPA03010269A (es)	2001-05-11	2004-05-05	Vertex Pharma	Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
JP2005508979A (ja)	2001-10-29	2005-04-07	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	システインプロテアーゼの可逆性インヒビターとして有用な化合物
US6635771B2 (en) *	2001-12-03	2003-10-21	Wyeth	N-benzhydryl indole compounds
KR100447255B1 (ko)	2001-12-31	2004-09-07	주식회사 하이닉스반도체	입자 함침층 조성물 및 이를 이용한 연마 패드
AU2003211093A1 (en) *	2002-02-15	2003-09-09	The Regents Of The University Of Michigan	Inhibitors of rgs proteins
US7235558B2 (en)	2002-06-06	2007-06-26	Sanofi-Aventis Deutschland Gmbh	Inhibitors of the GPIb—vWF interaction, their preparation and use
US6989392B2 (en)	2002-06-18	2006-01-24	Abbott Laboratories	2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006510661A (ja)	2002-12-06	2006-03-30	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体

2000
- 2000-08-09 US US09/635,266 patent/US6455734B1/en not_active Expired - Fee Related
2001
- 2001-08-09 DE DE60119385T patent/DE60119385D1/de not_active Expired - Lifetime
- 2001-08-09 AT AT01961984T patent/ATE324881T1/de not_active IP Right Cessation
- 2001-08-09 JP JP2002517051A patent/JP2004508299A/ja active Pending
- 2001-08-09 AU AU2001283203A patent/AU2001283203A1/en not_active Abandoned
- 2001-08-09 CA CA002418951A patent/CA2418951A1/en not_active Abandoned
- 2001-08-09 WO PCT/US2001/024909 patent/WO2002011714A2/en not_active Ceased
- 2001-08-09 EP EP01961984A patent/EP1355638B1/de not_active Expired - Lifetime
- 2001-08-09 NZ NZ523915A patent/NZ523915A/en unknown
2002
- 2002-08-29 US US10/230,133 patent/US6664420B2/en not_active Expired - Fee Related
2003
- 2003-10-28 US US10/695,536 patent/US6855826B2/en not_active Expired - Fee Related
2004
- 2004-12-21 US US11/018,690 patent/US7041829B2/en not_active Expired - Fee Related
2005
- 2005-12-02 US US11/292,460 patent/US7132537B2/en not_active Expired - Fee Related
2006
- 2006-08-29 US US11/512,024 patent/US7211667B2/en not_active Expired - Fee Related
2007
- 2007-03-28 US US11/729,101 patent/US7405311B2/en not_active Expired - Fee Related
2008
- 2008-06-24 US US12/214,943 patent/US7619097B2/en not_active Expired - Fee Related
2009
- 2009-10-16 US US12/589,064 patent/US7795450B2/en not_active Expired - Fee Related
2010
- 2010-07-23 US US12/842,642 patent/US7982048B2/en not_active Expired - Fee Related
2011
- 2011-06-08 US US13/156,026 patent/US8129545B2/en not_active Expired - Fee Related
2012
- 2012-02-08 US US13/369,027 patent/US20120142781A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6455734B1 (en)	2002-09-24
AU2001283203A1 (en)	2002-02-18
US20060069259A1 (en)	2006-03-30
US7795450B2 (en)	2010-09-14
US8129545B2 (en)	2012-03-06
EP1355638A2 (de)	2003-10-29
NZ523915A (en)	2005-05-27
US6855826B2 (en)	2005-02-15
US20040110692A1 (en)	2004-06-10
US7132537B2 (en)	2006-11-07
EP1355638B1 (de)	2006-05-03
US6664420B2 (en)	2003-12-16
US20110281923A1 (en)	2011-11-17
US20070197659A1 (en)	2007-08-23
WO2002011714A3 (en)	2003-08-14
US20100048711A1 (en)	2010-02-25
US20030040625A1 (en)	2003-02-27
JP2004508299A (ja)	2004-03-18
US7041829B2 (en)	2006-05-09
US20090030080A1 (en)	2009-01-29
US7405311B2 (en)	2008-07-29
DE60119385D1 (de)	2006-06-08
CA2418951A1 (en)	2002-02-14
US20110021633A1 (en)	2011-01-27
US20070010535A1 (en)	2007-01-11
US7211667B2 (en)	2007-05-01
WO2002011714A2 (en)	2002-02-14
US20120142781A1 (en)	2012-06-07
US20050096279A1 (en)	2005-05-05
US7982048B2 (en)	2011-07-19
US7619097B2 (en)	2009-11-17

Legal Events

Date	Code	Title	Description
2006-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
EA200501798A1 (ru)	2006-10-27	Новые пептиды, которые связываются с рецептором к эритропоэтину
CY1111225T1 (el)	2015-06-11	Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
NO20072352L (no)	2007-05-31	Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
BR9713186A (pt)	1999-11-03	Inibidores de metaloprotease 1,3-diheterocìclicos
ATE440087T1 (de)	2009-09-15	2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
EA200500782A1 (ru)	2005-10-27	Лечение геморрагического шока
DE69429527D1 (de)	2002-01-31	Inhibitoren von beta-amyloid-protein-herstellung
NO20055852L (no)	2006-02-13	Nye peptider som binder til erytropoietinreseptoren
ATE548354T1 (de)	2012-03-15	Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
EA200501710A1 (ru)	2006-06-30	Замещённые карбоновые кислоты
NO20010446L (no)	2001-01-26	Substituert anilidforbindelser og metoder
BRPI0516132A (pt)	2007-12-04	compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
DE69827651D1 (de)	2004-12-23	Verwendung von tempol zur behandlung von essentiellem hochdruck
EA199900669A1 (ru)	2000-06-26	Промежуточные соединения для получения замещенных n-[аминоиминометил или аминометил)фенил]пропиламидов
CY1107564T1 (el)	2013-03-13	Πολυμορφο του 4-[2-[4-[1-(2-αιθοξυαιθυλ)-1η-βενζιμιδαζολ-2-υλ]-1-πιπepιδινυλ]αιθυλ]αιθυλ-αλφα, αλφα-διμεθυλ-βενζενοξικου οξεος
ATE452884T1 (de)	2010-01-15	Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
EA200601212A1 (ru)	2006-10-27	Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
ATE420654T1 (de)	2009-01-15	Behandlung von muskeldystrophien und verwandter erkrankungen
NO20052272L (no)	2005-06-06	CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
DE602004031356D1 (de)	2011-03-24	Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
MA27880A1 (fr)	2006-05-02	Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE60140707D1 (de)	2010-01-14	GSK3-Polypeptide
DE60119385D1 (de)	2006-06-08	Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen
DE602004031631D1 (de)	2011-04-14	Verwendung von betain zur behandlung von claudicatio intermittens
NO20070780L (no)	2007-05-11	Celloverflateprotein.